HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Problems Remain In Calif. Consumer Products Reg, Slated For October

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Council faults the latest and likely last draft of California’s Safer Consumer Products regs for its lack of a weight-of-evidence approach to decision making and inadequate trade-secret protections, among other shortcomings.

You may also be interested in...



California Alternatives Analysis Guide Short On Details For Compliance

The state’s guidance for conducting stage 1 alternatives analyses under its Safer Consumer Products program lacks detail on the "most basic internal process for evaluating data and other product information" to inform compliance decisions, an industry coalitions say.

California Alternatives Analysis Guide Short On Details For Compliance

The state’s guidance for conducting stage 1 alternatives analyses under its Safer Consumer Products program lacks detail on the "most basic internal process for evaluating data and other product information" to inform compliance decisions, an industry coalitions say.

California DTSC's Alternative Analyses Guide Falls Short Of Industry Needs

The Department of Toxic Substances Control's guidance for conducting the stage-1 alternatives analyses under California's Safer Consumer Products program lacks detail on the agency's "most basic internal process for evaluating data and other product information" to inform compliance decisions, industry coalitions say. The groups cite numerous areas in need of clarification in November comments to the agency.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel